Trial Profile
A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Amcasertib (Primary)
- Indications Cholangiocarcinoma; Liver cancer
- Focus Therapeutic Use
- Sponsors Boston Biomedical; Sumitomo Pharma America; Sumitomo Pharma Oncology
- 22 Jan 2021 Status changed from active, no longer recruiting to completed.
- 22 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Nov 2017 Status changed from recruiting to active, no longer recruiting.